Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise
Retrieved on:
Monday, May 16, 2022
Bowel obstruction, Senior, Anti-inflammatory, Colon, Wall, Inflammation, Epithelium, Degenerative disease, UC, Disease, Hyperplasia, Soft tissue injury, U.S. Securities and Exchange Commission, Retina, Ulcerative colitis, Patient, Biology, Homeostasis, Infection, Hearing loss, Coronavirus, Wnt signaling pathway, Liver, Cochlea, COVID-19, Colitis, Cell, LRP6, Kidney, Research, Inflammatory bowel disease, SAN, Hepatology, DSS, Probability, Lists of disasters, Forward-looking statement, Central nervous system, Technology, Regeneration, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, ECCO, Tissue, GLOBE, Pharmaceutical industry, FZD5, WNT
The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.
Key Points:
- The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.
- SZN-1326 demonstrated the most rapid and robust repair of the injured colon epithelium without affecting normal epithelium and without causing hyperplasia.
- In the intestine, Wnt signaling plays an important role in maintaining integrity of the epithelium as part of tissue homeostasis and during injury repair.
- Surrozen designed an antibody-based platform that generates potent Wnt mimetics, which specifically target select Fzd receptors and co-receptors.